Genus PLC (GNS) is a publicly traded biotechnology business based in the UK. In the week up to 28 September Genus shares plunged 8.51% to a closing position of 2580p. Over the last 12 months, Genus's share price has fallen by 9.86% from 5465p. Genus is listed on the London Stock Exchange (LSE). All prices are listed in pence sterling.
Best for
0% commission
Best for
Beginner investments
Best for
Mobile app
Best for
Referral bonus
Share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.
| Platform | Platform fee | Min. initial deposit | Trading fee estimate | |
|---|---|---|---|---|
|
£0 | $10 | £0.00 £492.60 total |
Capital at risk |
|
£0 | £250 | £8.00 £500.60 total |
Capital at risk |
|
£0 | No minimum | £0.00 £492.60 total |
Capital at risk |
 |
£0 | £1 | £11.95 £504.55 total |
Capital at risk |
 |
£0 | £0.01 | £1.82 £494.42 total |
Capital at risk |
 |
£9.99 per month | No minimum | £7.99 £500.59 total |
Capital at risk |
 |
£36 per year | £20 | £9.50 £502.10 total |
Capital at risk |
Full comparison of share dealing platforms
Historical closes compared with the last close of 4926p
| 1 week (2022-09-23) | 80.44% |
|---|---|
| 1 month (2022-08-30) | 94.86% |
| 3 months (2022-06-30) | 96.41% |
| 6 months (2022-03-29) | 71.04% |
| 2 years (2020-09-30) | 27.82% |
|---|---|
| 3 years (2019-09-30) | 76.43% |
| 5 years (2017-09-29) | 134.80% |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page.
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value.
Genus's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 42x. In other words, Genus shares trade at around 42x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the FTSE 250 at the end of September 2019 (19.71). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Genus's EBITDA (earnings before interest, taxes, depreciation and amortisation) is £79.8 million.
The EBITDA is a measure of a Genus's overall financial performance and is widely used to measure a its profitability.
| Open | 5070p |
|---|---|
| High | 5070p |
| Low | 4856p |
| Close | 4926p |
| Previous close | 4942p |
| Change | -16p |
| Change % | -0.3238% |
| Volume | 77,126 |
| 52-week range | 2186p - 5694.4455p |
|---|---|
| 50-day moving average | 2656.08p |
| 200-day moving average | 3062.225p |
| Wall St. target price | 4303.86p |
| PE ratio | 42.4194 |
| Dividend yield | 32p (1.17%) |
| Earnings per share (TTM) | 0.62p |
Dividend yield: 1.17% of stock value
Forward annual dividend yield: 1.17% of stock value
Dividend payout ratio: 51.61% of net profits
Genus has recently paid out dividends equivalent to 1.17% of its share value annually.
Genus has paid out, on average, around 51.61% of recent net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.17% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), shareholders could enjoy a 1.17% return on their shares, in the form of dividend payments. In Genus's case, that would currently equate to about 32p per share.
Genus's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
The latest dividend was paid out to all shareholders who bought their shares by 17 November 2022 (the "ex-dividend date").
Over the last 12 months, Genus's shares have ranged in value from as little as 2186p up to 5694.4455p. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (LSE average) beta is 1, while Genus's is 0.5227. This would suggest that Genus's shares are less volatile than average (for this exchange).
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Ever wondered how to buy shares in Veru? We explain how and compare a range of providers that can give you access to many brands, including Veru.
Ever wondered how to buy shares in C4 Therapeutics? We explain how and compare a range of providers that can give you access to many brands, including C4 Therapeutics.
Ever wondered how to buy shares in Clever Leaves? We explain how and compare a range of providers that can give you access to many brands, including Clever Leaves.
Mental health stocks can be rewarding, but there are risks involved that could impact your profits. Find out how to invest in companies in the mental health industry.
Pharma stocks can be rewarding, but there are risks involved that could impact your profits. Find out the best way to invest in pharma stock.
Ever wondered how to buy shares in Bone Biologics? We explain how and compare a range of providers that can give you access to many brands, including Bone Biologics.
Ever wondered how to buy shares in Adagio Therapeutics? We explain how and compare a range of providers that can give you access to many brands, including Adagio.
Ever wondered how to buy shares in Bolt Biotherapeutics? We explain how and compare a range of providers that can give you access to many brands, including Bolt Biotherapeutics.
Ever wondered how to buy shares in Vallon Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Vallon Pharmaceuticals.
Ever wondered how to buy shares in Qualigen Therapeutics? We explain how and compare a range of providers that can give you access to many brands, including Qualigen.
